Neuropeptides as Autocrine Growth Factors in Cancer Cells

Author(s): Terry W. Moody , Daniel Chan , Jan Fahrenkrug , Robert T. Jensen .

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 6 , 2003

Abstract:

Neuropeptides can function as autocrine growth factors in cancer cells. High levels of bombesin (BB) and neurotensin (NT)-like immunoreactivity are present in small cell lung cancer (SCLC), a neuroendocrine tumor. Vasoactive intestinal peptide (VIP) stimulates and somatostatin (SST) inhibits the release of BB-like peptides from SCLC cells. BB-like peptides bind to BB2 receptors, which are present on the cell surface. BB-like peptides stimulate the mitogen activated protein kinase (MAPK) cascade leading to increased expression of nuclear oncogenes and growth factors in SCLC cells. Due to the high density of neuropeptide receptors present on the cell surface, SST analogs have been radiolabeled to image neuroendocrine tumors. VIP receptors are present in many epithelial cancers including breast, colon, non-small cell lung cancer (NSCLC), pancreatic and prostate cancers. Due to the high density of VIP receptors on lung cancer cells, radiolabeled VIP agonists may be used to image these tumors. VIP receptor antagonists, such as VIPhybrid, inhibit the growth of cancer cell lines in vitro and in vivo. VIPhybrid and SR48692, a NT receptor antagonist, potentiate the cytotoxicity of chemotherapeutic drugs. These results suggest that neuropeptide receptor antagonists may be useful in the treatment of cancer.

Keywords: bombesin, neurotensin, somatostatin, vasoactive intestinal peptide, lung cancer

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 6
Year: 2003
Page: [495 - 509]
Pages: 15
DOI: 10.2174/1381612033391621
Price: $58

Article Metrics

PDF: 34